Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of LadRx.

    Client Virtual Booth

    LADRX

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    LadRx
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    11726 San Vicente Blvd. Suite 650 Los Angeles, California 90049
    Telephone
    Telephone
    (310) 826-5648
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ladrxcorp.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

    Details:

    With the termination, LadRx regains control of INNO-206 (aldoxorubicin), a rationally-engineered cytotoxic which delivers well-established anti-cancer agent, doxorubicin, into the tumor.


    Lead Product(s): Aldoxorubicin

    Therapeutic Area: Oncology Product Name: INNO-206

    Highest Development Status: Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: ImmunityBio

    Deal Size: $356.0 million Upfront Cash: Undisclosed

    Deal Type: Termination June 03, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

    Details:

    Under the agreement, XOMA has acquired the royalty and milestone rights associated with two assets from LadRx Corporation, BRX-345 (arimoclomol), an oral therapeutic for Niemann-Pick disease type C, and aldoxorubicin, an albumin-linked formulation of doxorubicin.


    Lead Product(s): Arimoclomol

    Therapeutic Area: Rare Diseases and Disorders Product Name: BRX-345

    Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: XOMA

    Deal Size: $58.6 million Upfront Cash: $5.0 million

    Deal Type: Agreement January 11, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

    Details:

    The Company expects to use the proceeds to advance its lead novel LADR-based anti-cancer drug, LADR-7 (AE-keto-sulf07) towards an IND filing with the FDA.


    Lead Product(s): AE-Keto-Sulf07

    Therapeutic Area: Oncology Product Name: LADR7

    Highest Development Status: IND EnablingProduct Type: Large molecule

    Partner/Sponsor/Collaborator: XOMA

    Deal Size: $11.0 million Upfront Cash: Undisclosed

    Deal Type: Financing June 22, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    LadRx Highlights Patent Issued for Its LADR Technology

    Details:

    INNO-206 (aldoxorubicin) is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker and expresses antitumor efficacy and toxicity.


    Lead Product(s): Aldoxorubicin

    Therapeutic Area: Oncology Product Name: INNO-206

    Highest Development Status: Phase IIProduct Type:

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search